Horizon Licenses Use of GS Knockout CHO K1 Cell Line to NGM Bio
Complete the form below to unlock access to ALL audio articles.
Horizon, a company specializing in the application of gene editing and gene modulation for cell line engineering, has announced that it will license its gene-edited Glutamine Synthetase (GS) knockout Chinese Hamster Ovary (CHO) K1 cell line to NGM Biopharmaceuticals. A clinical stage biopharmaceutical company, NGM is focused on developing novel therapeutics based on scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases.
Horizon’s proprietary GS knockout CHO K1 cell line and protocols aim to facilitate the development of stable cell lines for the expression of antibodies and other recombinant proteins. The Company also licenses a CHO expression system to pharmaceutical, biotechnology, and biosimilar companies, as well as contract manufacturing organizations. To enable companies to move from the DNA sequence of their potential biotherapeutic to clinical manufacturing as simply and rapidly as possible, the complete system includes the GS knockout CHO K1 cell line, a comprehensive package of supporting documentation, and an expression vector supplied under license from DNATwoPointO, Inc.
